Qyuns Therapeutics Co Ltd (2509) Fair Value & Analysis
Healthcare · HK · Market cap HK$3.3B
Fair value as of: Aug 13, 2026
From 24 valuation models · updated 3 days ago
Fair value updated Aug 13, 2026, revised from HK$25.50 to HK$25.52 (+0.1%) since Aug 5, 2026. Share price +10.9% over the past month.
A strong business, screening 45% undervalued on our models.
What matters now
- The rarer combination: high quality (88/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The price is below even our cautious bear case (HK$19.57). The market is more pessimistic than our downside scenario.
Price vs Fair Value (2 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
29‑month range HK$6.30 – HK$35.34 · fair‑value band HK$19.57 – HK$31.48 · the HK$17.64 price screens below the HK$25.52 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Qyuns Therapeutics Co Ltd (2509) currently trades at HK$17.64, while our model-based Fair Value estimate is HK$25.52, implying the stock looks roughly 44.7% undervalued today. The Quality Score stands at 88/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Qyuns Therapeutics Co Ltd generated revenue of HK$807M at a net margin of 39.0%. It earns a return on equity of 68.3%. The balance sheet holds a net cash position of HK$382M. The stock trades on a trailing P/E of 9.1 (as of Jul 2, 2026). Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$19.57 (bear case) to HK$31.48 (bull case); at HK$17.64, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 52% below its 52-week high and 34% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -47% fair-value upside, at 45%, 2509 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (HK$62.78) versus Asset-Based (HK$2.08). Highest evidence: Growth DCF (80).
Notify me when 2509 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 84 · Market factors (momentum, volatility) 19
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, engages in the research and development of biologic therapies for autoimmune and allergic diseases in China.
Full company description
Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, engages in the research and development of biologic therapies for autoimmune and allergic diseases in China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor, which completed Phase III clinical trial for the treatment of ankylosing spondylitis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra that is in Phase III clinical trial for treating prurigo nodularis. The company also develops QX001S, which is an IL-12/L-23p40 inhibitor for psoriasis under the SAILEXIN brand. In addition, the company develops QX008N, a humanized IgG1 mAb targeting thymic stromal lymphopoietin that is in Phase Ib clinical trial to treat moderate-to-severe asthma and chronic obstructive pulmonary disease; and QX004N, an IL-23p19 inhibitor, which is in Phase II clinical trial to treat psoriasis and Crohn's disease. The company also develops QX027N, an anti-TSLPxIL-13 bispecific antibody that targets AD and asthma indications; QX030N, a IL-23p19/TL1A clinical stage long-acting bispecific antibody for the treatment of inflammatory bowel diseases; QX031N, a clinical stage TSLP/IL-33 long-acting bispecific antibody for the treatment of chronic obstructive pulmonary disease and asthma; and QX035N, a bispecific antibody for the treatment of respiratory and dermatology diseases. Further, it manufactures and sells pharmaceutical products; and provides technical consultation services. Qyuns Therapeutics Co., Ltd. was incorporated in 2015 and is headquartered in Taizhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Qyuns Therapeutics Co Ltd reported revenue of HK$786M in FY2025 versus HK$21.3M in FY2021, a compound +146.3%/yr. Reported net income was HK$306M in FY2025.
Watch 2509: get an alert when its fair value changes →
Peer Group
Biotechnology · 605 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $525.73 | $278.78 | -47% |
| Regeneron Pharmaceuticals, Inc REGN | $797.99 | $594.40 | -26% |
| Samsung Biologics Co 207940 | 1,549,000 KRW | 1,055,793 KRW | -32% |
| Celltrion, Inc 068270 | 202,000 KRW | 74,519 KRW | -63% |
| WuXi Biologics (Cayman) Inc 2269 | HK$45.70 | HK$30.58 | -33% |
| Innovent Biologics, Inc 1801 | HK$95.55 | HK$19.68 | -79% |
| Genmab A/S GMAB | kr 2,037 | kr 250.07 | -88% |
| Sino Biopharmaceutical Limited 1177 | HK$4.87 | HK$3.37 | -31% |
| RemeGen Co 688331 | ¥131.87 | ¥23.19 | -82% |
| ALTEOGEN Inc 196170 | 314,000 KRW | 39,476 KRW | -87% |
Compare Qyuns Therapeutics Co Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Qyuns Therapeutics Co Ltd (2509) overvalued or undervalued?
What is the fair value of 2509?
What is the quality score of 2509?
What is the revenue of Qyuns Therapeutics Co Ltd (2509)?
What is the net profit margin of 2509?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Qyuns Therapeutics Co Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.